BRAF and melanoma: A more-complete characterization of these minor alterations would not only expand our knowledge of RAS pathway regulation but might also reveal new opportunities for innovative treatment strategies against the non-BRAF mutant genetic subtypes of melanoma, for which there are currently no targeted therapy options.